Cannabis - EU-27

EU-27

Revenue in the Cannabis market in EU-27 is forecasted to reach US$5.32bn in 2024.
Projected revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 3.31%, leading to a market volume of US$6.26bn by 2029.
When compared globally, the United States is expected to generate the highest revenue (US$42.98bn in 2024).
In terms of per person revenues in 2024, US$0.07k are generated in relation to the total population figures.
In the EU-27, the Cannabis market is rapidly expanding as more countries legalize medical and recreational use, creating a lucrative investment landscape.

Key regions: United States, Canada, Netherlands, Germany, Thailand

Market

Region

Region comparison

Currency

Analyst Opinion

The Cannabis market in EU-27 has been experiencing significant growth and development in recent years.

Customer preferences: Consumers in the EU-27 have shown a growing interest in cannabis products for both medicinal and recreational purposes. There is a shift towards more acceptance and legalization of cannabis across various countries in the region, leading to an increase in demand for a wide range of cannabis-based products.

Trends in the market: In countries like Germany and the Netherlands, there is a trend towards the legalization of medical cannabis, which has opened up new opportunities for companies in the pharmaceutical and healthcare sectors. Additionally, there is a rising popularity of CBD products in countries like France and Italy, driven by increasing awareness of their potential health benefits.

Local special circumstances: Each country in the EU-27 has its own regulations and policies regarding cannabis, leading to a diverse market landscape. For example, Spain and Portugal have favorable climate conditions for cannabis cultivation, making them key players in the production of cannabis for both domestic and export markets. On the other hand, countries like Poland and Hungary have more conservative views on cannabis, which can impact the market dynamics in those regions.

Underlying macroeconomic factors: The growing acceptance and legalization of cannabis in the EU-27 can be attributed to changing societal attitudes, as well as increasing awareness of the potential economic benefits associated with the cannabis industry. As more countries in the region explore the potential of cannabis for medical and recreational use, the market is expected to continue its growth trajectory in the coming years.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.